id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_zigdntq6q5f5jchqh2dodnilou	Stuart A. McCluskey	Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery	2005.0	7	.pdf	application/pdf	5092	486	65	patients, 214 received PET and their RBC transfusion rate was RBC transfusion in patients who received PET was 0.36 Because of this clear efficacy, PET gained regulatory approval in 1996 for use in anemic patients (pretreatment Hb concentration of > 100 g·L–1 to # 130 we implemented a more practical PET dosing schedule for eligible anemic patients undergoing TJA at our schedule for PET in reducing allogeneic RBC transfusion in patients undergoing TJA. A second method was the use of propensity analysis to match patients who received PET to similar In comparison, 18.3% (153/837) of non-anemic patients received RBC transfusions (P < 0.0001; In the 770 anemic patients, the rate of RBC transfusion was 16.4% (35/214) in those who received g·L–1) patients undergoing elective TJA as part of routine practice that employed a more flexible dosing regimen than those used in randomized clinical trials. patients who received RBC transfusions.	./cache/work_zigdntq6q5f5jchqh2dodnilou.pdf	./txt/work_zigdntq6q5f5jchqh2dodnilou.txt